Scholar Rock (SRRK)
(Delayed Data from NSDQ)
$31.96 USD
+0.56 (1.78%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $31.95 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SRRK 31.96 +0.56(1.78%)
Will SRRK be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SRRK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRRK
Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross?
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal
SRRK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SRRK
Scholar Rock Holding (SRRK) Sees Price Target Revision by BMO Capital | SRRK Stock News
Decoding Scholar Rock Holding Corp (SRRK): A Strategic SWOT Insight
Q2 2025 Scholar Rock Holding Corp Earnings Call Transcript
SRRK Crosses Below Key Moving Average Level
Scholar Rock outlines Q3 2025 U.S. apitegromab launch plans amid regulatory progress and global expansion focus